8-K: Chrome Holding Co. Files Chapter 11 Liquidation Plan

Chrome Holding Co. and its subsidiaries filed a joint Chapter 11 plan to wind down operations and distribute assets, following the sale of most assets for $302.5 million and ongoing data breach settlements.

Summary

• Chrome Holding Co. (formerly 23andMe Holding Co.) and its subsidiaries (Debtors) filed voluntary Chapter 11 petitions on March 23, 2025, to stabilize their business and sell assets.
• The Debtors sold substantially all of their assets to TTAM Research Institute for a total purchase price of $302.5 million in cash on July 14, 2025.
• The proposed plan includes the sale of the Debtors' Lemonaid telehealth business for $2.5 million, subject to higher and better offers.
• The plan aims to wind down the Debtors' estates and conclude their Chapter 11 Cases through a confirmed Chapter 11 plan.
• The Joint Plan of Chrome Holding Co. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code and a related Disclosure Statement were filed on August 15, 2025.
• Holders of Allowed Other Secured Claims and Allowed Other Priority Claims are unimpaired and presumed to accept the plan, receiving 100% recovery.
• Holders of U.S. Data Breach Class Settlement Claims, U.S. Data Breach Arbitration Settlement Group Claims, Canadian Data Breach Class Settlement Claims, Chrome Commercial Claims, and Chrome Other General Unsecured Claims are impaired but projected to receive 100% recovery.
• Holders of Lemonaid Commercial Claims and Lemonaid Other General Unsecured Claims are impaired, with projected recoveries to be determined (TBD).
• Holders of HoldCo Interests (equity) are impaired, with projected recoveries to be determined (TBD).
• The plan establishes a Plan Administration Trust, funded by asset sale proceeds, cash on hand, retained causes of action, and cyber insurance proceeds, to facilitate distributions.
• Approximately 170,800 timely proofs of claim and an additional 46,530 late-filed claims have been asserted against the Debtors, with an aggregate asserted amount exceeding $7 trillion.
• The U.S. Data Breach Class Settlement Agreement provides a minimum allowed amount of $30 million and a cap of $50 million for U.S. Data Breach Class Settlement Claims.
• The Canadian Data Breach Class Settlement Agreement caps the aggregate cash distribution for Canadian Data Breach Class Settlement Claims at $3.99 million.
• Chrome Holding Co.'s Class A common stock was delisted from NASDAQ on March 31, 2025, and now trades on the over-the-counter market.

Sentiment

Score: 2

Explanation: The company is undergoing Chapter 11 liquidation, having sold most of its assets and planning to sell its remaining business. This indicates severe financial distress and business failure. While asset sales and settlements are in progress, the overall situation is highly negative for existing equity holders and reflects a significant downturn.

Positives

• Successfully completed the sale of substantially all assets for $302.5 million, providing significant cash for creditor distributions.
• Repaid in full all outstanding debtor-in-possession (DIP) financing, which had a commitment of up to $60 million.
• Reached settlement agreements for major data breach class actions in the U.S. and Canada, which cap potential liabilities related to the Cyber Security Incident.
• The proposed plan aims to maximize value for all stakeholders and facilitate an efficient wind-down and distribution process, avoiding a potentially more costly Chapter 7 liquidation.
• The plan is structured with the intent to pay all creditors in full, and potentially provide distributions to equity holders, although the latter is uncertain.

Negatives

• The company has not recognized any net profits since its inception, indicating a history of unprofitability.
• Experienced severe liquidity pressures due to macroeconomic headwinds, rising inflation, declining consumer interest in genetic testing, and increased competition.
• Suffered a significant data breach in October 2023, impacting approximately seven million customers, leading to numerous class action lawsuits, arbitration claims, and regulatory investigations.
• The company's stock was delisted from NASDAQ due to the Chapter 11 filing, and now trades on the less liquid over-the-counter market.
• The aggregate asserted amount of all claims against the Debtors exceeds $7 trillion, far surpassing the proceeds from asset sales, creating significant uncertainty for recoveries.
• Ongoing appeals of the asset sale order by the State of California and Global BioData Trust (CAVEAT) introduce continued legal uncertainty.
• The Lemonaid telehealth business sale for $2.5 million is subject to higher offers and regulatory approvals, with no assurance of closing.
• The company faces ongoing liquidity restraints and expects to incur significant professional fees during the Chapter 11 process.
• The company's U.S. federal net operating loss (NOL) carryforwards and other tax attributes will not survive the implementation of the plan.

Risks

• Uncertainty regarding the amount of time the Debtors may spend in bankruptcy.
• High costs of bankruptcy cases and related fees.
• Bankruptcy Court rulings in the Chapter 11 Cases may not be favorable.
• Risk of conversion to a Chapter 7 liquidation case.
• Risk of dismissal of one or more Chapter 11 Cases.
• Uncertainty whether the Lemonaid Sale Transaction will be consummated.
• Risk that results or developments contemplated by the plan may not materialize as anticipated.
• Risk that the Debtors may seek to amend, waive, modify, or withdraw the Plan.
• Risk that other parties in interest may propose an alternative chapter 11 plan.
• Risk that the amount of administrative claims are greater than expected.
• Risk that the actual amount of Allowed Claims and Allowed Interests are materially greater than expected.
• Impact of inflation on operations.
• Impact of unanticipated market and economic conditions.
• Risks that certain estimates and assumptions might ultimately prove to be incorrect.
• Risks of being party to certain legal proceedings and associated expenses.
• Uncertainty of the Governmental Bar Date outcome and potential material claims.
• Risks that the timing of distributions differ from expectations.
• Changes in interest rates.
• Risks associated with bankruptcy, insolvency, and/or other creditor protection proceedings in foreign jurisdictions.
• Immaturity and volatility of the telehealth market.
• Ability to attract new customers and patients for Lemonaid.
• Success of customer engagements and alignment with cost expectations.
• Maintenance and enhancement of the company's brand.
• Impact of fierce competition in the telehealth industry.
• Risks associated with governmental regulation and ability to prescribe certain medications.
• Compliance with extensive regulations.
• Reliance on third parties for compounded medications and FDA/state requirements.
• Risks associated with key sole suppliers.
• Reliance on other companies for platform operation and revenue generation.
• Liquidity requirements and adequacy of capital resources.
• Changes in policies of domestic and foreign government and regulatory authorities.
• Possible adverse impacts of regulatory, legislative, tax, or other judicial developments.
• Force majeure events and continuing economic impact related to COVID-19.
• Risk that releases, injunctions, and exculpations provisions may not be approved.
• Risk of non-occurrence of the Effective Date.
• Risk of failing to satisfy vote requirement for plan confirmation.
• Risk that the plan is based upon assumptions that may prove incorrect.
• Contingencies may affect distributions to holders of allowed claims or interests.
• The Debtors may be adversely affected by potential litigation, including appeals.
• The Debtors cannot guarantee the preservation of their tax attributes (NOLs).
• Settlement agreements may not be approved and/or are subject to termination.

Future Outlook

The plan's primary objective is to maximize value for all stakeholders and distribute available property in accordance with Bankruptcy Code priorities, aiming to avoid lengthy delays and significant costs associated with Chapter 7 liquidation. The Debtors intend for the Plan Administration Trust to be a liquidating trust for U.S. federal income tax purposes. The Debtors believe that the plan will produce a recovery for the Holders of Claims and Interests that is not less than what would be achieved in a Chapter 7 liquidation, and that following consummation, the Debtors will have sufficient funds to make all required payments without further financial restructuring.

Management Comments

• The Special Committee of the Board of Directors of Chrome Holding Co. and the boards of directors, managers, or members, as applicable, of each of its Debtor subsidiaries have approved the transactions contemplated by the Plan and recommend that all Holders of Claims and Interests, Eligible Class Members, and Class Counsel whose votes are being solicited submit ballots and vote to accept the Plan.
• The Debtors believe that Confirmation of the Plan will avoid the lengthy delay and significant cost of liquidation under chapter 7 of the Bankruptcy Code.
• The Debtors believe that the Plan accomplishes this objective and is in the best interest of the Estates.
• The Debtors believe the Plan, and the transactions, settlements, and compromises embodied therein, are the best alternative available to the estates.
• The Debtors believe that the Plan will produce a recovery for the Holders of Claims and Interests that is not less than what would be achieved in a Chapter 7 liquidation.
• The Debtors believe that, following consummation of the Plan, the Debtors will have sufficient funds to make all payments required by the Plan without the need for any further financial restructuring.
• In the opinion of the Debtors, any alternative other than confirmation of the Plan could result in extensive delays and increased administrative expenses, ultimately resulting in smaller distributions to the Holders of Allowed Claims and Allowed Interests than those set forth in the Plan.

Industry Context

The company, a pioneer in direct-to-consumer genetic testing and telehealth, faced significant industry challenges. These included macroeconomic headwinds, rising inflation, and a general decline in consumer interest and demand for genetic testing. The telehealth market, where the company's Lemonaid business operates, is described as relatively new, unproven, and highly competitive, with increasing competition from traditional healthcare providers expanding into telehealth and new direct-to-consumer entrants. Regulatory scrutiny, particularly concerning genetic data transfer and the prescription of controlled substances, also impacts the industry, requiring careful compliance and potentially affecting business operations.

Comparison to Industry Standards

• The company pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports, setting a high standard in the genetic testing industry.
• The company developed one of the world's largest crowdsourced platforms for genetic research, comprised of data from over 15 million customers, indicating a significant scale in genetic data collection.
• The company's consumer segment faced increased competition in both the ancestry testing and telehealth industries, suggesting a struggle to maintain market share against rivals.
• Many current and potential competitors in the telehealth industry may have greater name and brand recognition, longer operating histories, and significantly greater resources than Lemonaid, potentially offering similar products and services at more attractive prices, indicating a challenging competitive landscape for the company's telehealth segment.

Management Changes

Corporate Governance

Legal Proceedings

• Over 40 putative class action lawsuits were filed in U.S. federal courts (Cyber Class Action MDL No. 3098) related to the October 2023 data breach.
• Approximately 35,000 arbitration claims were asserted or threatened in the U.S. related to the data breach.
• Nine actions were filed in California state courts related to the data breach, which were stayed until May 22, 2025.
• Three class actions were filed in Canadian courts related to the data breach.
• A pre-arbitration demand was made by a U.K. firm on behalf of 3,720 customers.
• The Federal Trade Commission (FTC) served a civil investigative demand (CID) seeking information related to the data breach.
• A Multi-State Attorneys General investigation was initiated regarding the data breach.
• 12 foreign regulators inquired about the data breach, including a joint investigation initiated by Canada and the U.K.
• The United Kingdom Information Commissioners Office imposed a penalty of £2,310,000 (approximately $3 million U.S. dollars) related to the Cyber Security Incident.
• The Spanish Data Protection Authority imposed a fine of €2,400,000 (approximately $2.8 million U.S. dollars) related to the Cyber Security Incident.
• The South Dakota Attorney General served a civil investigative demand.
• Shareholder demand letters relating to prepetition conduct were received.
• Adversary proceedings were initiated by certain states in the Bankruptcy Court seeking a determination that consumers have property interests in their genetic data.
• Global BioData Trust (CAVEAT) filed a motion to file an Amici Curiae Brief, arguing for recognition of the company's genetic database as quasi-property held in trust.
• Appeals of the Sale Order by the State of California and CAVEAT to the District Court and Eighth Circuit were filed, with requests for stays denied, but appeals remain pending.
• Settlement agreements were reached for the U.S. Data Breach Class Settlement, U.S. Data Breach Arbitration Settlement, and Canadian Data Breach Class Settlement.

Related Party Transactions

• Ms. Anne Wojcicki, co-founder, former chief executive officer, and current member of the Board of Directors, expressed her intent to consider making an offer to acquire the outstanding equity of the Company held by unaffiliated public stockholders.
• Ms. Wojcicki and New Mountain Capital L.L.C. submitted a joint non-binding indication of interest on February 20, 2025, to acquire all outstanding common stock not owned by Ms. Wojcicki or her affiliates for $2.53 per share (post-reverse stock split). New Mountain later withdrew from this proposal.
• Ms. Wojcicki submitted subsequent non-binding proposals on March 2, 2025 ($0.41/share), and March 6, 2025 ($0.41/share upfront plus contingent value rights), which were rejected by the Special Committee.
• Ms. Wojcicki offered to provide $30 million of unsecured financing for the company's operations through the closing of a potential transaction, and later proposed an additional $20 million of capital, but these offers were part of rejected proposals.
• An entity affiliated with Ms. Wojcicki, ABeeC 2.0 LLC, converted 4,931,692 shares of Class B Common Stock into Class A Common Stock on June 9, 2025.

Stakeholder Impact

• Shareholders (HoldCo Interests): Will receive a portion of Class B Plan Administration Trust Interests. Projected recoveries are 'TBD', implying a high likelihood of minimal or no recovery, and trading in common stock is explicitly stated as highly speculative.
• Creditors (Various Classes): Most allowed claims (Other Secured, Other Priority, U.S. Data Breach Class Settlement, U.S. Data Breach Arbitration Settlement Group, Canadian Data Breach Class Settlement, Chrome Commercial, Chrome Other General Unsecured, Lemonaid Commercial) are projected to receive 100% recovery, primarily through the Plan Administration Trust. However, the actual amount of allowed claims is uncertain and could materially differ.
• Employees: The company implemented a significant headcount reduction (approximately 40% in November 2024). The plan provides for payment of prepetition wages and continuation of employee benefits programs.
• Customers: Customers impacted by the data breach are subject to settlement agreements that provide for distributions and privacy/monitoring services. Customers of the Lemonaid telehealth business will be affected by its sale.
• Suppliers/Vendors: Critical vendors' prepetition claims were authorized for payment. Other trade creditors (Chrome Commercial Claims, Lemonaid Commercial Claims) are projected to receive 100% recovery.
• Regulatory Authorities: The company faces ongoing investigations and has incurred significant penalties from regulatory bodies (e.g., UK ICO, Spanish DPA), indicating a negative impact from regulatory scrutiny.

Next Steps

• The Confirmation Hearing for the Plan is proposed to be held on November 13, 2025.
• The Voting Deadline for accepting or rejecting the Plan is October 31, 2025 (4:00 p.m. CT).
• California and CAVEAT must file their brief on appeal in the District Court by October 6, 2025, and their reply by October 20, 2025.
• The Debtors will seek preliminary and final approval of the U.S. and Canadian Data Breach Class Settlements.
• The Debtors will file a motion to assume the U.S. Data Breach Arbitration Settlement Agreement.
• A Plan Administrator will be appointed to wind down the Debtors' affairs, pay and reconcile claims, and administer the Plan.
• The Plan Administrator will file a certificate of dissolution for the Chrome Debtors and complete all final federal, state, and local tax returns.
• The Plan Administrator will be responsible for filing final monthly and all subsequent quarterly reports.
• The Plan Administrator will collect all applicable proceeds of Insurance Policies, including Cyber Insurance Policies, and create appropriate reserves.
• The Plan Administrator shall promptly file all documents required to close the Chapter 11 Cases after full administration.

Key Dates

Recommendation

The company is undergoing Chapter 11 liquidation, having sold most of its core assets and planning to sell its remaining business. Existing equity (HoldCo Interests) is at the bottom of the waterfall recovery, with 'TBD' projected recoveries, implying a high likelihood of minimal or no recovery. The stock has been delisted from NASDAQ and trades on the OTC market, with the company explicitly stating that trading is 'highly speculative and poses substantial risks' and that trading prices 'may bear little or no relationship to the actual recovery, if any.' This is a clear signal of severe impairment and impending loss for equity holders, warranting a 'sell' recommendation.

Keywords

Chapter 11, Bankruptcy, Liquidation, Asset Sale, Data Breach, Telehealth, Genetic Testing, SEC Filing, Corporate Restructuring, Claims Settlement, Creditor Recovery, TTAM Research Institute, Lemonaid Health, Chrome Holding Co., 23andMe